ACOR Acorda Therapeutics Inc

Price (delayed)

$4.07

Market cap

$38.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.32

Enterprise value

$195.68M

Sector: Healthcare
Industry: Biotechnology

Highlights

ACOR's net income has soared by 64% YoY
The company's EPS has surged by 64% YoY
ACOR's quick ratio has plunged by 59% YoY but it is up by 8% from the previous quarter
The company's equity fell by 24% QoQ and by 23% YoY
Acorda Therapeutics's gross profit has decreased by 24% YoY and by 11% from the previous quarter

Key stats

What are the main financial stats of ACOR
Market
Shares outstanding
9.49M
Market cap
$38.62M
Enterprise value
$195.68M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.14
Price to sales (P/S)
0.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.28
Earnings
Revenue
$152.97M
EBIT
-$77.09M
EBITDA
-$35.8M
Free cash flow
-$65.4M
Per share
EPS
-$12.32
Free cash flow per share
-$8.09
Book value per share
$29.77
Revenue per share
$18.92
TBVPS
$32.87
Balance sheet
Total assets
$632.68M
Total liabilities
$394.73M
Debt
$259.95M
Equity
$237.96M
Working capital
$84.08M
Liquidity
Debt to equity
1.09
Current ratio
1.61
Quick ratio
0.9
Net debt/EBITDA
-4.39
Margins
EBITDA margin
-23.4%
Gross margin
78.1%
Net margin
-65.1%
Operating margin
-97.4%
Efficiency
Return on assets
-14.1%
Return on equity
-34.7%
Return on invested capital
-20.7%
Return on capital employed
-15.6%
Return on sales
-50.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACOR stock price

How has the Acorda Therapeutics stock price performed over time
Intraday
-2.86%
1 week
-0.25%
1 month
-29.09%
1 year
-36.01%
YTD
-1.69%
QTD
-16.43%

Financial performance

How have Acorda Therapeutics's revenue and profit performed over time
Revenue
$152.97M
Gross profit
$119.45M
Operating income
-$148.92M
Net income
-$99.59M
Gross margin
78.1%
Net margin
-65.1%
ACOR's operating margin has dropped by 80% since the previous quarter but it has surged by 53% year-on-year
Acorda Therapeutics's operating income has shrunk by 66% QoQ but it has surged by 63% YoY
ACOR's net income has soared by 64% YoY
Acorda Therapeutics's net margin has surged by 54% YoY

Growth

What is Acorda Therapeutics's growth rate over time

Valuation

What is Acorda Therapeutics stock price valuation
P/E
N/A
P/B
0.14
P/S
0.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.28
The company's EPS has surged by 64% YoY
ACOR's P/B is 87% below its 5-year quarterly average of 1.1 but 40% above its last 4 quarters average of 0.1
The company's equity fell by 24% QoQ and by 23% YoY
ACOR's price to sales (P/S) is 83% lower than its 5-year quarterly average of 1.3 but 10% higher than its last 4 quarters average of 0.2
The company's revenue fell by 20% YoY and by 7% QoQ

Efficiency

How efficient is Acorda Therapeutics business performance
The company's return on sales has surged by 62% YoY
ACOR's ROIC has soared by 52% year-on-year
Acorda Therapeutics's ROA has increased by 47% YoY
Acorda Therapeutics's ROE has increased by 46% YoY

Dividends

What is ACOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACOR.

Financial health

How did Acorda Therapeutics financials performed over time
ACOR's total assets is 60% greater than its total liabilities
ACOR's quick ratio has plunged by 59% YoY but it is up by 8% from the previous quarter
Acorda Therapeutics's current ratio has increased by 48% QoQ but it has decreased by 31% YoY
Acorda Therapeutics's debt is 9% higher than its equity
Acorda Therapeutics's debt to equity has increased by 36% YoY and by 33% from the previous quarter
The company's equity fell by 24% QoQ and by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.